1 Market Overview

1.1 Product Overview and Scope of Chemotherapy Induced Peripheral Neuropathy Treatment

1.2 Classification of Chemotherapy Induced Peripheral Neuropathy Treatment by Type

1.2.1 Overview: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type in 2020

1.2.3 Calcium Channel α2-delta Ligands

1.2.4 Antidepressants

1.2.5 Opioids

1.2.6 Others

1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market by Application

1.3.1 Overview: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Platinum Agents

1.3.3 Taxanes

1.3.4 Vinca Alkaloids

1.3.5 Others

1.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size & Forecast

1.5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast by Region

1.5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region, (2016-2021)

1.5.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Prospect (2016-2026)

1.5.4 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Prospect (2016-2026)

1.5.6 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers

1.6.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints

1.6.3 Chemotherapy Induced Peripheral Neuropathy Treatment Trends Analysis

2 Company Profiles

2.1 Aptinyx Inc

2.1.1 Aptinyx Inc Details

2.1.2 Aptinyx Inc Major Business

2.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

2.1.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 Aptinyx Inc Recent Developments and Future Plans

2.2 Asahi Kasei Pharma Corp

2.2.1 Asahi Kasei Pharma Corp Details

2.2.2 Asahi Kasei Pharma Corp Major Business

2.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

2.2.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 Asahi Kasei Pharma Corp Recent Developments and Future Plans

2.3 Regenacy Pharmaceuticals

2.3.1 Regenacy Pharmaceuticals Details

2.3.2 Regenacy Pharmaceuticals Major Business

2.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

2.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 Regenacy Pharmaceuticals Recent Developments and Future Plans

2.4 MAKScientific LLC

2.4.1 MAKScientific LLC Details

2.4.2 MAKScientific LLC Major Business

2.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

2.4.4 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 MAKScientific LLC Recent Developments and Future Plans

2.5 Metys Pharmaceuticals AG

2.5.1 Metys Pharmaceuticals AG Details

2.5.2 Metys Pharmaceuticals AG Major Business

2.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

2.5.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Metys Pharmaceuticals AG Recent Developments and Future Plans

2.6 Nemus Bioscience Inc

2.6.1 Nemus Bioscience Inc Details

2.6.2 Nemus Bioscience Inc Major Business

2.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

2.6.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 Nemus Bioscience Inc Recent Developments and Future Plans

2.7 PledPharma

2.7.1 PledPharma Details

2.7.2 PledPharma Major Business

2.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

2.7.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 PledPharma Recent Developments and Future Plans

2.8 Sova Pharmaceuticals Inc

2.8.1 Sova Pharmaceuticals Inc Details

2.8.2 Sova Pharmaceuticals Inc Major Business

2.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

2.8.4 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.8.5 Sova Pharmaceuticals Inc Recent Developments and Future Plans

2.9 DermaXon LLC

2.9.1 DermaXon LLC Details

2.9.2 DermaXon LLC Major Business

2.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

2.9.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.9.5 DermaXon LLC Recent Developments and Future Plans

2.10 Kineta Inc

2.10.1 Kineta Inc Details

2.10.2 Kineta Inc Major Business

2.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

2.10.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.10.5 Kineta Inc Recent Developments and Future Plans

2.11 Krenitsky Pharmaceuticals Inc

2.11.1 Krenitsky Pharmaceuticals Inc Details

2.11.2 Krenitsky Pharmaceuticals Inc Major Business

2.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

2.11.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.11.5 Krenitsky Pharmaceuticals Inc Recent Developments and Future Plans

2.12 PeriphaGen

2.12.1 PeriphaGen Details

2.12.2 PeriphaGen Major Business

2.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

2.12.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.12.5 PeriphaGen Recent Developments and Future Plans

2.13 Apexian Pharma

2.13.1 Apexian Pharma Details

2.13.2 Apexian Pharma Major Business

2.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

2.13.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.13.5 Apexian Pharma Recent Developments and Future Plans

2.14 WinSanTor

2.14.1 WinSanTor Details

2.14.2 WinSanTor Major Business

2.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

2.14.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.14.5 WinSanTor Recent Developments and Future Plans

2.15 Solasia Pharma K.K.

2.15.1 Solasia Pharma K.K. Details

2.15.2 Solasia Pharma K.K. Major Business

2.15.3 Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

2.15.4 Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.15.5 Solasia Pharma K.K. Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 5 Chemotherapy Induced Peripheral Neuropathy Treatment Players Market Share

3.2.2 Top 10 Chemotherapy Induced Peripheral Neuropathy Treatment Players Market Share

3.2.3 Market Competition Trend

3.3 Chemotherapy Induced Peripheral Neuropathy Treatment Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Type (2016-2021)

4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2016-2021)

5.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2016-2026)

6.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2016-2026)

6.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country

6.3.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2016-2026)

6.3.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast (2016-2026)

6.3.3 Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast (2016-2026)

6.3.4 Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2016-2026)

7.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2016-2026)

7.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country

7.3.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2016-2026)

7.3.2 Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast (2016-2026)

7.3.3 France Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast (2016-2026)

7.3.4 United Kingdom Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast (2016-2026)

7.3.5 Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast (2016-2026)

7.3.6 Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2016-2026)

8.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2016-2026)

8.3 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region

8.3.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2016-2026)

8.3.2 China Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast (2016-2026)

8.3.3 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast (2016-2026)

8.3.4 South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast (2016-2026)

8.3.5 India Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast (2016-2026)

8.3.7 Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2016-2026)

9.2 South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2016-2026)

9.3 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country

9.3.1 South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2016-2026)

9.3.2 Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast (2016-2026)

9.3.3 Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2016-2026)

10.2 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2016-2026)

10.3 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country

10.3.1 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2016-2026)

10.3.2 Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast (2016-2026)

10.3.4 UAE Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million) by Region (2016-2021)

Table 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2021-2026)

Table 6. Aptinyx Inc Corporate Information, Head Office, and Major Competitors

Table 7. Aptinyx Inc Major Business

Table 8. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 9. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. Asahi Kasei Pharma Corp Corporate Information, Head Office, and Major Competitors

Table 11. Asahi Kasei Pharma Corp Major Business

Table 12. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 13. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. Regenacy Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 15. Regenacy Pharmaceuticals Major Business

Table 16. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 17. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. MAKScientific LLC Corporate Information, Head Office, and Major Competitors

Table 19. MAKScientific LLC Major Business

Table 20. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 21. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Metys Pharmaceuticals AG Corporate Information, Head Office, and Major Competitors

Table 23. Metys Pharmaceuticals AG Major Business

Table 24. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 25. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. Nemus Bioscience Inc Corporate Information, Head Office, and Major Competitors

Table 27. Nemus Bioscience Inc Major Business

Table 28. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 29. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. PledPharma Corporate Information, Head Office, and Major Competitors

Table 31. PledPharma Major Business

Table 32. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 33. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. Sova Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors

Table 35. Sova Pharmaceuticals Inc Major Business

Table 36. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 37. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 38. DermaXon LLC Corporate Information, Head Office, and Major Competitors

Table 39. DermaXon LLC Major Business

Table 40. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 41. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 42. Kineta Inc Corporate Information, Head Office, and Major Competitors

Table 43. Kineta Inc Major Business

Table 44. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 45. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 46. Krenitsky Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors

Table 47. Krenitsky Pharmaceuticals Inc Major Business

Table 48. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 49. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 50. PeriphaGen Corporate Information, Head Office, and Major Competitors

Table 51. PeriphaGen Major Business

Table 52. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 53. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 54. Apexian Pharma Corporate Information, Head Office, and Major Competitors

Table 55. Apexian Pharma Major Business

Table 56. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 57. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 58. WinSanTor Corporate Information, Head Office, and Major Competitors

Table 59. WinSanTor Major Business

Table 60. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 61. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 62. Solasia Pharma K.K. Corporate Information, Head Office, and Major Competitors

Table 63. Solasia Pharma K.K. Major Business

Table 64. Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Product and Solutions

Table 65. Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 66. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million) by Players (2019-2021)

Table 67. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Players (2019-2021)

Table 68. Breakdown of Chemotherapy Induced Peripheral Neuropathy Treatment by Company Type (Tier 1, Tier 2 and Tier 3)

Table 69. Chemotherapy Induced Peripheral Neuropathy Treatment Players Head Office, Products and Services Provided

Table 70. Chemotherapy Induced Peripheral Neuropathy Treatment Mergers & Acquisitions in the Past Five Years

Table 71. Chemotherapy Induced Peripheral Neuropathy Treatment New Entrants and Expansion Plans

Table 72. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million) by Type (2016-2021)

Table 73. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Type (2016-2021)

Table 74. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Type (2021-2026)

Table 75. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2016-2021)

Table 76. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Application (2021-2026)

Table 77. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2016-2021) & (USD Million)

Table 78. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021-2026) & (USD Million)

Table 79. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2016-2021) & (USD Million)

Table 80. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021-2026) & (USD Million)

Table 81. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2016-2021) & (USD Million)

Table 82. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2021-2026) & (USD Million)

Table 83. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2016-2021) & (USD Million)

Table 84. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021-2026) & (USD Million)

Table 85. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2016-2021) & (USD Million)

Table 86. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021-2026) & (USD Million)

Table 87. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2016-2021) & (USD Million)

Table 88. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2021-2026) & (USD Million)

Table 89. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2016-2021) & (USD Million)

Table 90. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021-2026) & (USD Million)

Table 91. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2016-2021) & (USD Million)

Table 92. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021-2026) & (USD Million)

Table 93. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2016-2021) & (USD Million)

Table 94. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2021-2026) & (USD Million)

Table 95. South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2016-2021) & (USD Million)

Table 96. South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021-2026) & (USD Million)

Table 97. South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2016-2021) & (USD Million)

Table 98. South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021-2026) & (USD Million)

Table 99. South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2016-2021) & (USD Million)

Table 100. South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2021-2026) & (USD Million)

Table 101. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2016-2021) & (USD Million)

Table 102. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2021-2026) & (USD Million)

Table 103. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2016-2021) & (USD Million)

Table 104. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2021-2026) & (USD Million)

Table 105. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2016-2021) & (USD Million)

Table 106. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. Chemotherapy Induced Peripheral Neuropathy Treatment Picture

Figure 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type in 2020

Figure 3. Calcium Channel α2-delta Ligands

Figure 4. Antidepressants

Figure 5. Opioids

Figure 6. Others

Figure 7. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application in 2020

Figure 8. Platinum Agents Picture

Figure 9. Taxanes Picture

Figure 10. Vinca Alkaloids Picture

Figure 11. Others Picture

Figure 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Forecast (2016-2026) & (USD Million)

Figure 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2016-2026)

Figure 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region in 2020

Figure 16. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 17. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 18. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 19. South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 20. Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers

Figure 21. Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints

Figure 22. Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends

Figure 23. Aptinyx Inc Recent Developments and Future Plans

Figure 24. Asahi Kasei Pharma Corp Recent Developments and Future Plans

Figure 25. Regenacy Pharmaceuticals Recent Developments and Future Plans

Figure 26. MAKScientific LLC Recent Developments and Future Plans

Figure 27. Metys Pharmaceuticals AG Recent Developments and Future Plans

Figure 28. Nemus Bioscience Inc Recent Developments and Future Plans

Figure 29. PledPharma Recent Developments and Future Plans

Figure 30. Sova Pharmaceuticals Inc Recent Developments and Future Plans

Figure 31. DermaXon LLC Recent Developments and Future Plans

Figure 32. Kineta Inc Recent Developments and Future Plans

Figure 33. Krenitsky Pharmaceuticals Inc Recent Developments and Future Plans

Figure 34. PeriphaGen Recent Developments and Future Plans

Figure 35. Apexian Pharma Recent Developments and Future Plans

Figure 36. WinSanTor Recent Developments and Future Plans

Figure 37. Solasia Pharma K.K. Recent Developments and Future Plans

Figure 39. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Players in 2020

Figure 40. Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 41. Global Top 3 Players Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share in 2020

Figure 42. Global Top 10 Players Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share in 2020

Figure 43. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 44. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Type in 2020

Figure 45. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share Forecast by Type (2021-2026)

Figure 46. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Application in 2020

Figure 47. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share Forecast by Application (2021-2026)

Figure 48. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2026)

Figure 49. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2026)

Figure 50. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2016-2026)

Figure 51. United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 52. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 53. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 54. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2026)

Figure 55. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2026)

Figure 56. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2016-2026)

Figure 57. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 58. France Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 59. United Kingdom Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 60. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 61. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 62. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2026)

Figure 63. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2026)

Figure 64. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2016-2026)

Figure 65. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 66. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 67. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 68. India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 69. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 70. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 71. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2026)

Figure 72. South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2026)

Figure 73. South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2016-2026)

Figure 74. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 75. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 76. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2016-2026)

Figure 77. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2016-2026)

Figure 78. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2016-2026)

Figure 79. Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 80. Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 81. UAE Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 82. Methodology

Figure 83. Research Process and Data Source